Current Immunotherapeutic Approaches in Pancreatic Cancer

被引:69
|
作者
Koido, Shigeo [1 ,2 ,3 ]
Homma, Sadamu [3 ]
Takahara, Akitaka [1 ]
Namiki, Yoshihisa [2 ]
Tsukinaga, Shintaro [1 ]
Mitobe, Jimi [1 ]
Odahara, Shunichi [1 ]
Yukawa, Toyokazu [1 ]
Matsudaira, Hiroshi [1 ]
Nagatsuma, Keisuke [1 ]
Uchiyama, Kan [1 ]
Satoh, Kenichi [1 ]
Ito, Masaki [3 ]
Komita, Hideo [1 ]
Arakawa, Hiroshi [1 ]
Ohkusa, Toshifumi [1 ,2 ]
Gong, Jianlin [4 ]
Tajiri, Hisao [1 ]
机构
[1] Jikei Univ, Sch Med, Dept Internal Med, Div Gastroenterol & Hepatol, Tokyo 1058461, Japan
[2] Jikei Univ, Sch Med, Inst Clin Med & Res, Tokyo 1058461, Japan
[3] Jikei Univ, Sch Med, Dept Oncol, Inst DNA Med, Tokyo 1058461, Japan
[4] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA
关键词
GROWTH-FACTOR RECEPTOR; COLONY-STIMULATING FACTOR; CYTOTOXIC T-LYMPHOCYTES; PHASE-III TRIAL; PERSONALIZED PEPTIDE VACCINATION; UNIVERSAL TUMOR-ANTIGEN; CELL-BASED VACCINATION; HUMAN DENDRITIC CELLS; PLUS GEMCITABINE; CARCINOMA CELLS;
D O I
10.1155/2011/267539
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Pancreatic cancer is a highly aggressive and notoriously difficult to treat. As the vast majority of patients are diagnosed at advanced stage of the disease, only a small population is curative by surgical resection. Although gemcitabine-based chemotherapy is typically offered as standard of care, most patients do not survive longer than 6 months. Thus, new therapeutic approaches are needed. Pancreatic cancer cells that develop gemcitabine resistance would still be suitable targets for immunotherapy. Therefore, one promising treatment approach may be immunotherapy that is designed to target pancreatic-cancer-associated antigens. In this paper, we detail recent work in immunotherapy and the advances in concept of combination therapy of immunotherapy and chemotherapy. We offer our perspective on how to increase the clinical efficacy of immunotherapies for pancreatic cancer.
引用
收藏
页数:15
相关论文
共 50 条
  • [31] Current Approaches to the Management of Locally Advanced Pancreatic Cancer
    Hannah R. Malinosky
    John H. Stewart
    Omeed Moaven
    Current Surgery Reports, 2023, 11 : 260 - 269
  • [32] Current and emerging immunotherapeutic approaches for biliary tract cancers
    Zhen-Gang Yuan
    Tian-Mei Zeng
    Chen-Jie Tao
    Hepatobiliary&PancreaticDiseasesInternational, 2022, 21 (05) : 440 - 449
  • [33] Current and emerging immunotherapeutic approaches to the treatment of multiple myeloma
    Swan, Dawn
    Lynch, Kevin
    Gurney, Mark
    O'Dwyer, Michael
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2019, 10 : 1 - 21
  • [34] Current and emerging immunotherapeutic approaches for biliary tract cancers
    Yuan, Zhen-Gang
    Zeng, Tian -Mei
    Tao, Chen-Jie
    HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, 2022, 21 (05) : 440 - 449
  • [35] Current immunotherapeutic approaches to diffuse intrinsic pontine glioma
    Lin, Catherine
    Smith, Christian
    Rutka, James
    FRONTIERS IN GENETICS, 2024, 15
  • [36] Current immunotherapeutic strategies in lung cancer
    Ruettinger, Dominik
    Hatz, Rudolf A.
    Jauch, Karl-Walter
    Fox, Bernard A.
    SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 2007, 16 (04) : 901 - +
  • [37] Current immunotherapeutic strategies in prostate cancer
    Grosso, Joseph F.
    Drake, Charles G.
    SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 2007, 16 (04) : 861 - +
  • [38] Current immunotherapeutic strategies in breast cancer
    Carson, William E., III
    Liang, Margaret I.
    SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 2007, 16 (04) : 841 - +
  • [39] Immune profiling and immunotherapeutic targets in pancreatic cancer
    Lenzo, Felicia L.
    Kato, Shumei
    Pabla, Sarabjot
    DePietro, Paul
    Nesline, Mary K.
    Conroy, Jeffrey M.
    Burgher, Blake
    Glenn, Sean T.
    Kuvshinoff, Boris
    Kurzrock, Razelle
    Morrison, Carl
    ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (02)
  • [40] Immunologic principles and immunotherapeutic approaches in ovarian cancer
    Knutson, KL
    Curiel, TJ
    Salazar, L
    Disis, ML
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2003, 17 (04) : 1051 - +